Valuation
- Market cap
- 93,552,000
- Revenue TTM
- $0
- Net income TTM
- $-77,740,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 3,735,800
- Avg volume
- 717,716
- Day's range
- $1.68 – $1.87
- Shares out
- 53,458,000
- Stochastic %K
- 81%
- Beta
- 1.35
- Analysts
- Strong Sell
- Price target
- $4.20
Company profile
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to...
Show more
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 609 642 6670
- Website
- https://www.pmvpharma.com
- Address
- 400 Alexander Park Drive, Suite 301, Princeton, United States
Latest news
No headlines yet.
